KLRS

Kalaris Therapeutics Inc

Oct 06 • 04:00PM ET

8.03

+1.39 20.93 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-7.58	Insider Own	74.58%	Shs Outstand	18.70M	Perf Week	26.46%
Market Cap	134.40M	Forward P/E	-	EPS next Y	-2.17	Insider Trans	0.00%	Shs Float	4.75M	Perf Month	73.81%
Enterprise Value	45.97M	PEG	-	EPS next Q	-0.60	Inst Own	7.07%	Short Float	10.88%	Perf Quarter	211.24%
Income	-43.94M	P/S	-	EPS this Y	73.70%	Inst Trans	-1.04%	Short Ratio	1.75	Perf Half Y	13.42%
Sales	0.00M	P/B	2.83	EPS next Y	25.73%	ROA	-39.26%	Short Interest	0.52M	Perf YTD	-16.87%
Book/sh	2.84	P/C	1.52	EPS next 5Y	55.30%	ROE	-50.68%	52W High	24.15 -66.75%	Perf Year	-57.68%
Cash/sh	5.28	P/FCF	-	EPS past 3/5Y	42.89% -6.86%	ROIC	-82.73%	52W Low	2.14 275.23%	Perf 3Y	-95.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	20.48% 15.70%	Perf 5Y	-98.70%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	73.18%	Oper. Margin	-	ATR (14)	0.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.98	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	74.47	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	11.98	EPS Q/Q	50.00%	SMA20	55.12%	Beta	0.40	Target Price	16.75
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	107.60%	Rel Volume	1.79	Prev Close	6.64
Employees	6	LT Debt/Eq	0.00	Earnings	Aug 13 BMO	SMA200	32.75%	Avg Volume	295.47K	Price	8.03
IPO	Jul 30, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-32.61% -	Trades		Volume	524,748	Change	20.93%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Raymond James	Strong Buy	$23
Jul-23-25	Resumed	Piper Sandler	Neutral	$3
May-07-25	Initiated	Leerink Partners	Outperform	$20
Apr-08-25	Initiated	William Blair	Outperform

Sep-15-25 03:26PM	UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
08:00AM	Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration (GlobeNewswire)
Sep-01-25 12:00PM	Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-25 08:00AM	Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -8.43%
Jun-02-25 08:00AM	Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference (GlobeNewswire)
11:03AM	Loading…
May-23-25 11:03AM	Kalaris to Participate at Stifel Ophthalmology Forum (GlobeNewswire)
May-14-25 08:00AM	Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-04-25 08:00AM	Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee (GlobeNewswire)
Mar-18-25 04:21PM	Kalaris Announces Closing of Merger with AlloVir (GlobeNewswire) +16.92%

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hagen Brett R	Chief Accounting Officer	Mar 26 '25	Sale	8.97	907	8,135	1,925	Mar 27 07:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRS

Kalaris Therapeutics Inc

Upgrade your FINVIZ experience